The Cooper Companies, Inc. $COO Shares Newly Acquired by Fulcrum Asset Management LLP

Fulcrum Asset Management LLP acquired a new position in shares of The Cooper Companies, Inc. (NASDAQ:COO) during the 3rd quarter, Holdings Channel.com reports. The fund acquired 14,562 shares of the medical device company’s stock, valued at approximately $823,000.

Several other large investors have also recently added to or reduced their stakes in COO. BlackRock Inc. acquired a new stake in shares of Cooper Companies during the second quarter worth approximately $1,077,762,000. Generation Investment Management LLP acquired a new position in shares of Cooper Companies in the 2nd quarter worth approximately $356,304,000. Jupiter Topco LLC acquired a new position in shares of Cooper Companies in the 2nd quarter worth approximately $305,074,000. JANA Partners Management LP grew its position in Cooper Companies by 0.5% during the 2nd quarter. JANA Partners Management LP now owns 3,582,480 shares of the medical device company’s stock worth $256,900,000 after acquiring an additional 17,322 shares during the last quarter. Finally, Wellington Management Group LLP grew its position in Cooper Companies by 3.1% during the 2nd quarter. Wellington Management Group LLP now owns 3,468,951 shares of the medical device company’s stock worth $248,758,000 after acquiring an additional 103,044 shares during the last quarter. 24.39% of the stock is owned by institutional investors.

Cooper Companies Trading Down 1.2%

Shares of NASDAQ COO opened at $62.19 on Friday. The Cooper Companies, Inc. has a 1-year low of $51.01 and a 1-year high of $89.83. The company has a market cap of $11.83 billion, a PE ratio of 21.23, a P/E/G ratio of 2.47 and a beta of 0.83. The company has a current ratio of 1.22, a quick ratio of 0.73 and a debt-to-equity ratio of 0.23. The company has a 50-day moving average of $58.65 and a two-hundred day moving average of $68.24.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 EPS for the quarter, beating the consensus estimate of $1.12 by $0.03. Cooper Companies had a net margin of 13.46% and a return on equity of 10.90%. The business had revenue of $1.07 billion for the quarter, compared to analysts’ expectations of $1.10 billion. During the same period in the prior year, the firm earned $0.49 earnings per share. Cooper Companies’s revenue was up .5% compared to the same quarter last year. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. As a group, equities analysts expect that The Cooper Companies, Inc. will post 4.53 earnings per share for the current fiscal year.

Cooper Companies announced that its board has authorized a share repurchase program on Wednesday, September 9th that permits the company to repurchase $3 billion in outstanding shares. This buyback authorization permits the medical device company to buy up to 22.7% of its shares through open market purchases. Stock buyback programs are typically an indication that the company’s leadership believes its shares are undervalued.

Insider Buying and Selling

In other news, Director Walter Rosebrough, Jr. acquired 7,000 shares of Cooper Companies stock in a transaction on Friday, September 11th. The shares were purchased at an average price of $54.11 per share, with a total value of $378,770.00. Following the acquisition, the director owned 17,000 shares in the company, valued at $919,870. This represents a 70.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Paul Keel acquired 4,701 shares of Cooper Companies stock in a transaction on Friday, September 11th. The shares were purchased at an average cost of $53.18 per share, for a total transaction of $249,999.18. Following the acquisition, the director owned 4,701 shares in the company, valued at approximately $249,999.18. This represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased 34,701 shares of company stock worth $1,880,039 in the last quarter. Insiders own 2.08% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on COO shares. Stifel Nicolaus set a $70.00 price target on Cooper Companies and gave the company a “buy” rating in a report on Thursday, September 10th. JPMorgan Chase & Co. reduced their price objective on Cooper Companies from $71.00 to $58.00 and set a “neutral” rating on the stock in a research note on Thursday, September 10th. Barclays raised Cooper Companies to a “hold” rating in a research note on Wednesday, October 7th. Wells Fargo & Company set a $61.00 target price on Cooper Companies and gave the stock an “equal weight” rating in a report on Thursday, September 10th. Finally, Bank of America lowered Cooper Companies from a “buy” rating to a “neutral” rating and lowered their target price for the company from $80.00 to $65.00 in a research note on Thursday, September 10th. Four analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $68.60.

Cooper Companies Profile

CooperCompanies is a global medical device company focused on vision care and women’s health. It serves customers in markets around the world through two primary businesses: CooperVision and CooperSurgical. CooperVision develops and sells contact lenses, including products for daily wear, astigmatism, presbyopia and myopia management. Its offerings include lenses made from silicone hydrogel and other materials, as well as specialty lens options. CooperSurgical provides products and services for women’s health and fertility care.